Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
BridgeBio Pharma, Inc. (NASDAQ: BBIO is among the 10 Fastest Growing NASDAQ Stocks to Buy Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating On February 25, 2026, Truist analyst Danielle Brill raised the firm's price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $95 from $86 and maintained a Buy rating on the shares. The analyst noted that the company had pre-announced Q4 Attruby sales of $146M in January, representing a 35% increase from Q3 and exceeding quarterly estimates. The performance was driven by an acceleration in the pace of new patient additions, which the analyst said appears to be continuing. Also on February 25, 2026, Morgan Stanley analyst Sean Laaman raised the firm's price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $98 from $96 and reiterated an Overweight rating after updating estimates following the company's Q4 report. On February 24, 2026, BridgeBio Pharma, Inc. (NASDAQ:BBIO) reported Q4 EPS of ($
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific ConferenceGlobeNewswire
- BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (BBIO) had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an "outperform" rating on the stock.MarketBeat
- BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- BridgeBio Pharma (BBIO) had its price target raised by Morgan Stanley from $96.00 to $98.00. They now have an "overweight" rating on the stock.MarketBeat
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 3/6/26 - Form 4
- 3/4/26 - Form 144
- 3/3/26 - Form 4
- BBIO's page on the SEC website